BioLineRx

BLRXPhase 3

Modi'in, IsraelFounded 2003biolinerx.com

BioLineRx is an Israeli biopharmaceutical company dedicated to identifying, in-licensing, and developing promising therapeutic candidates, primarily in oncology. Its strategic focus is on advancing motixafortide, which has demonstrated potential in multiple clinical settings, including as a stem cell mobilizer for autologous transplantation and as a combination therapy for metastatic pancreatic cancer. The company leverages a lean operational model to advance its pipeline through clinical development and strategic partnerships.

Market Cap

$4.7B

Founded

2003

Employees

50-100

Focus

Biotech

BLRX · Stock Price

USD 1086.001932.00 (-64.02%)

Historical price data

AI Company Overview

Technology Platform

A drug development platform focused on in-licensing and advancing clinical-stage therapeutic candidates, with core expertise in oncology clinical development and a lead asset targeting the CXCR4 pathway.

Pipeline Snapshot

19 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
BL-8040 1.25 mg/kg + G-CSF + Placebo +G-CSF	Multiple Myeloma	Phase 3
CYP-1020 + Risperidone	Schizophrenia	Phase 2/3
BL-7040	Ulcerative Colitis	Phase 2
Ara-C + BL-8040	Acute Myeloid Leukemia	Phase 2
BL-1020 + BL 1020 High Dose	Schizophrenia	Phase 2

Funding History

Total raised: $120M

PIPE$25MPerceptive AdvisorsSep 15, 2020

IPO$60MUndisclosedFeb 3, 2011

Series B$25MClal Biotechnology IndustriesNov 15, 2007

Series A$10MIsrael Biotech FundJun 15, 2005

Opportunities

The primary growth opportunity is the successful commercial launch and market penetration of APHEXDA® in the stem cell mobilization market.

A significant longer-term opportunity lies in advancing motixafortide for metastatic pancreatic cancer through a Phase 3 partnership, targeting a large, high-unmet-need oncology indication.

Further development in AML and potential new in-licensing deals provide additional avenues for growth.

Risk Factors

Key risks include commercial execution challenges as a first-time launcher in a competitive market, dependence on a single lead asset (motixafortide) across all programs, and a limited cash runway that requires successful revenue generation or additional financing.

Clinical and regulatory risks remain for pipeline programs not yet approved.

Competitive Landscape

BioLineRx competes directly with Sanofi's plerixafor (Mozobil®) in stem cell mobilization and faces a crowded, competitive field in pancreatic cancer therapeutics. Its differentiation is based on motixafortide's clinical profile, including efficient stem cell collection and a novel immune-mediated mechanism of action in solid tumors.